Europe’s medicines regulator has backed using AstraZeneca’s preventative COVID-19 therapy as a treatment for the disease and also endorsed another medicine as preventative option for another common virus.
Japan’s health ministry said on Monday that its panel of experts had agreed to approve manufacturing and sales of AstraZeneca’s COVID-19 preventive treatment Evusheld.
Monday morning, Innate Pharma announced that a planned futility interim analysis of the INTERLINK-1 Phase III trial sponsored by AstraZeneca failed to hit a pre-defined threshold for efficacy. This follows AstraZeneca’s Q2 report released on July 29 that included several other drugs and trials the company is axing.
AstraZeneca said it expected prescriptions of its COVID therapy to drive sales growth of more than 20% this year, as company reported second-quarter profit that topped analyst estimates.
AstraZeneca announced Wednesday that the results of the company’s TACKLE Phase III trial of Evusheld (tixagevimab and cilgavimab, formerly AZD7442) for the early outpatient treatment of mild-to-moderate COVID-19 have been published in The Lancet Respiratory Medicine. Results of the trial showed that Evusheld protected against progression to severe COVID-19 or death – from any cause – compared to placebo.